BASEL, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases.BioVersys joins forces with Hackensack Meridian Health (HMH) and their Center for Discovery and Innovation (CDI) to advance ansamycin antimicrobial candidates through an exclusive collaboration and license agreement.HMH is a leading US not-for-profit health care network, and the largest in New Jersey. NTMs are u ...